Coagulation Factor Deficiency Pipeline Insights Report, 2020 Featuring Sanofi, AryoGen Pharmed Co, Biotest, ICON, and Roche - ResearchAndMarkets.com
Coagulation Factor Deficiency Pipeline Insight, 2020 report outlays comprehensive insights of present clinical development scenario and growth prospects across the Coagulation Factor Deficiency market.
The "Coagulation Factor Deficiency - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
Coagulation Factor Deficiency Pipeline Insight, 2020 report outlays comprehensive insights of present clinical development scenario and growth prospects across the Coagulation Factor Deficiency market. A detailed picture of the Coagulation Factor Deficiency pipeline landscape is provided, which includes the disease overview and Coagulation Factor Deficiency treatment guidelines.
The assessment part of the report embraces in-depth Coagulation Factor Deficiency commercial assessment and clinical assessment of the Coagulation Factor Deficiency pipeline products from the pre-clinical developmental phase to the marketed phase.
In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Coagulation Factor Deficiency collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Coagulation Factor Deficiency with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Coagulation Factor Deficiency treatment.
- Coagulation Factor Deficiency key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Coagulation Factor Deficiency market.
Scope of the Report
- The Coagulation Factor Deficiency report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Coagulation Factor Deficiency across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Coagulation Factor Deficiency therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Coagulation Factor Deficiency research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Coagulation Factor Deficiency.
Key Topics Covered
1. Report Introduction
2. Coagulation Factor Deficiency
2.1. Overview
2.2. History
2.3. Coagulation Factor Deficiency Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Coagulation Factor Deficiency Diagnosis
2.6.1. Diagnostic Guidelines
3. Coagulation Factor Deficiency Current Treatment Patterns
3.1. Coagulation Factor Deficiency Treatment Guidelines
4. Coagulation Factor Deficiency - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Coagulation Factor Deficiency companies collaborations, Licensing, Acquisition - Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Coagulation Factor Deficiency Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Coagulation Factor Deficiency Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Coagulation Factor Deficiency Late Stage Products (Phase-III)
7. Coagulation Factor Deficiency Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Coagulation Factor Deficiency Discontinued Products
13. Coagulation Factor Deficiency Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
14. Coagulation Factor Deficiency Key Companies
15. Coagulation Factor Deficiency Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Coagulation Factor Deficiency Unmet Needs
18. Coagulation Factor Deficiency Future Perspectives
19. Coagulation Factor Deficiency Analyst Review
20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
Companies Mentioned
- Sanofi
- AryoGen Pharmed Co.
- Biotest
- ICON plc
- Hoffmann-La Roche
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/eznw9d
View source version on businesswire.com: https://www.businesswire.com/news/home/20200703005041/en/